
In a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.
Parents roam pharmacy aisles during the winter season of coughs and colds looking for El Dorado: a nonprescription cure for their child's ailment. After a review of 10 years' worth of evidence, however, the American College of Chest Physicians (ACCP) has concluded that most over-the-counter remedies are of no help for a common cold and its associated cough. Here is what a new ACCP clinical practice guidelines advise:






